Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA Journal Article


Authors: Mulhall, J. P.; Luo, X.; Zou, K. H.; Stecher, V.; Galaznik, A.
Article Title: Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA
Abstract: Aims: With self-reporting of erectile dysfunction (ED) in population-based surveys, men with ED may not represent men who are bothered sufficiently to seek an ED diagnosis and treatment. We used real-world observational data to assess: 1) the prevalence of ED diagnosis or treatment by age subgroups; and 2) the relationship of age with ED diagnosis or treatment after controlling for ED-related comorbidities in the USA. Methods: This cross-sectional study used de-identified claims data (MarketScan® databases; primary analysis). Sensitivity analysis was conducted using electronic health records (Humedica® database). Inclusion criteria were men aged ≥18 years with a 360-day continuous enrollment before the index date. We assessed the prevalence of ED diagnosis or phosphodiesterase type 5 inhibitor (PDE5I) prescription by age and the risk for ED diagnosis or treatment by age after controlling for comorbidities (hypertension, other cardiovascular disease, diabetes mellitus, depression and benign prostatic hyperplasia). Results: Of 19,833,939 men meeting inclusion criteria in the primary analysis, only 1 108 842 (5.6%) had an ED diagnosis or PDE5I prescription (mean [SD] age: 55.2 [11.2] years). Prevalence of ED diagnosis or treatment increased from age 18–29 years (0.4%) to 60–69 years (11.5%), then decreased in the seventh (11.0%), eighth (4.6%), and ninth (0.9%) decades. Men with ED diagnosis or treatment had a higher prevalence of any comorbidity (63.1% vs 29.3% for men without ED) and of each comorbid condition. In multivariate analyses, age was an independent risk factor for ED diagnosis or treatment. Sensitivity analysis provided consistent results. Conclusions: In a real-world setting in the USA, the prevalence of ED diagnosis or PDE5I treatment is generally low, increases with age, decreases in very old men, and is associated with increased prevalence of comorbidities. Age is an independent risk factor for ED diagnosis or treatment after controlling for comorbidities. © 2016 John Wiley & Sons Ltd
Keywords: comorbidity; observational study; age groups; erectile dysfunction; phosphodiesterase type 5 inhibitors; electronic health records; real-world claims data
Journal Title: International Journal of Clinical Practice
Volume: 70
Issue: 12
ISSN: 1368-5031
Publisher: Wiley Blackwell  
Date Published: 2016-12-01
Start Page: 1012
End Page: 1018
Language: English
DOI: 10.1111/ijcp.12908
PROVIDER: scopus
PUBMED: 28032424
PMCID: PMC5540144
DOI/URL:
Notes: Article -- Export Date: 2 February 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. John P Mulhall
    602 Mulhall